Adverse event profile by therapy cycle for vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in platinum-resistant ovarian cancer [1]
Title: Adverse event profile by therapy cycle for vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in platinum-resistant ovarian cancer
Author(s): Symanowski, James Thomas; Kutarska, Elzbieta; Bidzinski, Mariusz; et al.
Source: Journal of Clinical Oncology Volume: 31 Issue: 15 Published: 2013
Times Cited: 0
Nauka [2]